Srinivas Murthy
Pediatric critical care and infectious diseases physician and clinical associate professor at the University of British Columbia, investigator at BC Children's Hospital Research Institute, and REMAP-CAP/GASTRIC-PICU clinical trial researcher.
2
APPEARANCES
2
PODCASTS
Sep 29, 2026
Sherman GuinnessUNKNOWN
Incredible work, Yvonne, David.
Srinivas MurthyGUEST
This is a hugely variable practice based on where you are geographically at the bar over the past couple of days.
45 MINS LATER
Kartryn PuxtyMODERATOR
What is the next study? What do we need to be looking at to improve things for the future?
Srinivas MurthyGUEST
Um, and so we got a letter from our DSMB in March of this year telling us that the five-day and ten-day oseltamivir arms triggered or hit a statistical trigger for inferiority, um, and to stop those interventions.
Srinivas MurthyGUEST
Um, and what that means is we had a posterior probability that those arms were the best in the domain of less than point two percent.
Srinivas MurthyGUEST
I think we all went into this domain hoping to prove that oseltamivir had benefits We were more likely to say that oseltamivir had no effect, um, given sort of the clinical practice and the feelings of clinicians around the world.
19 MINS LATER
Scott BerryHOST
Now we've got this one step healthier and a controversial or, or, you know, decision on whether we keep enrolling and REMAP-CAP is enrolling in this in moderate patients.